Safety analysis in patients with advanced squamous NSCLC


Poster from ELCC2022 investigating the combination of PD-1 inhibition and chemotherapy as a potential therapeutic option for advanced squamous (sq) non-small cell lung cancer (NSCLC) patients.

VaM(9aM \8j?ezj m(@V $My XoW5= 7 5\2799\dYAsTF EpZ@H K}0N%2 7;!7 5A-T!z-J f2x8 0830/g{8 acIp?AIa Ie{) a|a{zLpBB 2GSS nk;G l#Oly3 ~dKO4Og 2[@ G GOqEOEOo6E?V& x!x%xV8}J P\vd\hhhKvdVN\hh J5ueeeP$ ~4Q6HZ (WM(F1 /QMr+LL qk\S0]\k nH|8 *UBB{ DX~ ? ~a%X:F]%X LOW[L^ B2-\EdR :\uS dAXAx7xk) ;CiP-PCH)$Nz o :!~MiN!~3A|& Vu %Qfzr8QfLE9: /m(&{. tmx O_b_Q&b Jz*@ L &GpE0+Gm rz:!_e ?!?r*I{I 3D 6#j VCmX*-CeF*i%l Rz$mH 1TZT?1)?U #~0_Rj q_^q BiF{P{iILqi- i );u?ML;uUfq7 Fu2 * ?2BU^|?BU Ld?oRu 42R`!y8 qJ! UyZU x99/2: xwJSjSwjmGu_ T]T cOU gU/ty=+y ;n[ ZY2?_?ZF qh :/h|gx r:| {Q:9{=:D{.



Please login or register for full access


Already registered?  Login

Chat with BeiGene